A Phase 3, Randomized, Double-blind, Placebo (Hepatitis B Vaccine) Controlled Clinical Trial of Recombinant (E. Coli) Hepatitis E Vaccine.

Trial Profile

A Phase 3, Randomized, Double-blind, Placebo (Hepatitis B Vaccine) Controlled Clinical Trial of Recombinant (E. Coli) Hepatitis E Vaccine.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 04 Jan 2018

At a glance

  • Drugs Recombinant hepatitis E vaccine (Hecolin) (Primary) ; Aluminium hydroxide; Hepatitis B vaccine recombinant
  • Indications Hepatitis B; Hepatitis E
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 04 Jan 2018 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verifiedJan 2016 ).
    • 23 Aug 2010 Primary endpoint 'Vaccine protective efficacy' has been met.
    • 23 Aug 2010 Results reported in Lancet.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top